Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291321 | 0.87 | PPARG (0.57) | MAPTKDM4EPOLBPPARGLMNA | |
| SCHEMBL8669167 | 0.73 | KDM4E (0.46) | KDM4EPPARGCYP3A4CYP2C9 | |
| SCHEMBL12291322 | 0.72 | PPARG (0.60) | MAPTKDM4EPOLBPPARGLMNA | |
| SCHEMBL6032172 | 0.72 | MAPT (0.53) | MAPTKDM4EPOLBPPARGMAOB | |
| SCHEMBL7469293 | 0.72 | MAPT (0.56) | MAPTKDM4EPOLBPPARGMAOB | |
| SCHEMBL12292921 | 0.71 | PPARG (0.52) | MAPTKDM4EPOLBPPARGMAOB | |
| SCHEMBL15503737 | 0.71 | MAPT (0.81) | MAPTKDM4EMAOBCYP1A2CYP3A4 | |
| SCHEMBL22461236 | 0.69 | ABCB1 (0.41) | CYP2C9CYP2C19LMNAALDH1A1 | |
| SCHEMBL27516237 | 0.68 | MAPT (0.51) | MAPTKDM4EPOLBPPARGMAOB | |
| SCHEMBL10876565 | 0.66 | POLB (0.48) | MAPTKDM4EPOLBPPARGCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | MAPT 4872/4885KDM4E 3930/4885POLB 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.